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Abstract
Purpose This study investigated the psychometric gain, if any, from the extension of the EQ-5D with a cognition bolt-on 
(EQ-5D + C) in a large cohort injury patients with and without traumatic brain injury (TBI).
Methods Hospitalized adult injury patients filled out a survey 1 month after initial admission. The survey included the EQ-
5D-3L, the cognition bolt-on item in EQ-5D format, and the visual analogue scale (EQ-VAS). We compared ceiling and other 
distributional effects between EQ-5D and EQ-5D + C and TBI and non-TBI group, and assessed convergent validity using 
the predictive association with EQ-VAS. Also, we assessed explanatory power using regression analysis, and classification 
efficiency using Shannon indices.
Results In total, 715 TBI patients and 1978 non-TBI patients filled out the EQ-5D + C and EQ-VAS. Perfect health was 
reported by 7.9% (N = 214) on the EQ-5D, and 7.3% (N = 197) on the EQ-5D + C. Convergent validity was highest for 
EQ-5D + C in the TBI group (Spearman’s rank correlation coefficient = − 0.736) and lowest for EQ-5D in the non-TBI group 
(Spearman’s rank correlation coefficient = − 0.652). For both TBI and non-TBI groups, the explanatory power of EQ-5D + C 
was slightly higher than of EQ-5D (R2 = 0.56 vs. 0.53 for TBI; R2 = 0.47 vs. 0.45 for non-TBI). Absolute classification effi-
ciency was higher for EQ-5D + C than for EQ-5D in both TBI groups, whereas relative classification efficiency was similar.
Conclusions Psychometric performance in general of both the EQ-5D and EQ-5D + C was better in TBI patients. Adding a 
cognitive bolt-on slightly improved the psychometric performance of the EQ-5D-3L.
Keywords HRQoL · EQ-5D · Cognition · TBI
Background
Currently, the measurement of health-related quality of life 
(HRQoL) is standard practice in evaluating the impact of 
health interventions [1]. HRQoL instruments can be cat-
egorized as generic and disease-specific measures, where a 
particular subclass of instruments are preference-based or 
‘utility’ measures, which can be used in economic evalu-
ations [2].
One of the generic instruments that is widely implemented 
is the EQ-5D. The EQ-5D is a self-assessment instrument that 
consists of five items on the following dimensions: mobil-
ity, self-care, usual activities, pain/discomfort, and anxiety/
depression and a visual analogue scale (VAS) [3]. The five 
dimensions can be scored using 3- or 5-level ordinal response 
options. One major advantage of the EQ-5D over other generic 
HRQoL measurement instruments is its brevity and subse-
quent low burden to fill out [4, 5]. However, a downside of 
the brevity may be that important information for HRQoL is 
not included in the EQ-5D dimensions, resulting in an instru-
ment that may be unable to capture certain health effects and 
that is not sensitive for the measurement of HRQoL of all 
conditions [6, 7]. Moreover, the EQ-5D is known to measure 
mainly physical dimensions of health, and lacking information 
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on social domains and sensitivity on psychological domains. 
Therefore, the EQ-5D is inconsistent in some populations [8]. 
A solution to increase coverage of the EQ-5D may be to add a 
dimension (a ‘bolt-on’) covering a specific health problem or 
dysfunction relevant to any particular condition or disease [9].
Over time, different bolt-on items to enrich the EQ-5D have 
been suggested. One of these bolt-on items is cognition [10]. 
Cognition can be operationalized with attributes like concen-
tration, memory, intellectual competence, and coherence [10]. 
A cognition bolt-on can be motivated from theoretical rea-
sons or from the pragmatic observation that cognition affecting 
diseases and conditions are common (dementia, Parkinson’s 
disease, injury, birth trauma, and congenital neurological 
conditions).
Even though many studies already use the cognition bolt-
on in the measurement of HRQoL with the EQ-5D, limited 
evidence on the added value of the cognitive bolt-on in patient 
groups with cognitive impairments exists. Wolfs et al. [11] 
found that in a population of elderly patients with cognitive 
impairments, the addition of a cognitive dimension had no 
effect on the construct validity. Ophuis et al. (Working paper: 
Health-related quality of life in injury patients: the added 
value of extending the EQ-5D-3L with a cognitive dimension) 
found that adding a cognition dimension to the EQ-5D in a 
heterogeneous sample of injury patients, including patients 
with mostly mild traumatic brain injury (TBI), had a similar 
impact on EQ-VAS scores as any of the existing five EQ-5D 
dimensions. However, both studies were lacking a clear differ-
entiation between the effects of adding a cognitive dimension 
to the EQ-5D in patients with and without suspected cognitive 
impairments. Therefore, this study can provide a more accurate 
insight in the additional value of a cognition dimension in the 
EQ-5D for TBI patients.
This study investigated the added value of a cognition 
dimension to the EQ-5D in a population of injury patients. 
The added value was analyzed in the form of the distributional 
benefit, the convergent validity, explanatory power, and clas-
sification efficiency of the EQ-5D and EQ-5D + C in a large 
sample of TBI and non-TBI patients who were admitted to the 
hospital due to their injury. We explored this by comparing 
ceiling and other distribution effects and convergent validity 
using the predictive association with the EQ-VAS. Also, we 
assessed the explanatory power using regression analyses, and 
classification efficiency using Shannon indices. Each of these 
aspects were determined for patients with and without TBI.
Methods
Research population and data collection
The Brabant Injury Outcome Surveillance (BIOS) study is 
a prospective cohort follow-up study of adult injury patients 
(18 years or older) who were admitted to one of the 10 par-
ticipating hospitals through the emergency department (ED), 
and who survived until hospital discharge [12]. The inclu-
sion of the study was conducted from 1 August 2015 until 
30 November 2016. The exclusion criteria were the inability 
to understand the Dutch language, the absence of a perma-
nent address of residence, and the suspected presence of a 
pathological fracture due to a malignancy or metastasis [12]. 
The study was approved by the Medical Ethics Committee 
of the Province of Brabant (METC code: NL50258.028.14).
The information on age, gender, nature, and severity of 
the injury were derived from the hospital registries. The 
severity of the injury was defined by the Injury Severity 
Score (ISS) [13]. The ISS is based on the square of the 
highest Abbreviated Injury Scales (AIS) of the three most 
severely injured body regions. The AIS describes the type, 
location, and severity of an injury [14]. Patients with an ISS 
of 16 and more are defined as severely injured. With the 
AIS score, it can be determined whether a patient has TBI, 
and what the severity level of the TBI is (mild, moderate, or 
severe). TBI was defined as mild with AIS head < 3, mod-
erate with AIS head = 3, and severe with an AIS head > 3 
[12]. Additional data were collected by a postal survey that 
patients received 1 month after injury [12]. The survey 
included the EQ-5D + C, the EQ-VAS, the highest level of 
education, and the existence of comorbidity.
HRQoL data
The EQ-5D consists of five items on different dimensions of 
health (one item per dimension): mobility, self-care, usual 
activity, pain/discomfort, and anxiety/depression. The ques-
tions on the different dimensions are available in two ver-
sions: a three-level version and a five-level version. We used 
the three-level version (EQ-5D-3L). In the 3L version, the 
answer options to each question are ‘no problems,’ ‘some 
problems,’ and ‘extreme problems’/‘unable to perform.’ 
Data can be represented by means of a profile summariz-
ing the respondents’ reported health problems defining the 
severity level (where 1 means no problems), e.g., ‘21332,’ 
and used in a descriptive way and, after summarizing 
response into an unweighted summary score, also referred 
to as ‘misery index’ (range 0–15) or a so-called 0–1 util-
ity score. Furthermore, the respondents were asked to rate 
their health from 0 to 100 on a VAS scale, where 0 is the 
worst imaginable health state, and 100 is the best imaginable 
health state. The score that is provided in this question by 
the respondent is the EQ-VAS score.
In the BIOS study, an additional dimension was added to 
the EQ-5D questionnaire for cognition. This bolt-on should 
capture information on cognitive functioning, operational-
ized as concentration, memory, and IQ [10]. The cogni-
tion bolt-on consisted of one question, and was framed like 
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the other dimension questions, with the same number of 
response options [3]. The instruction was (translated from 
the Dutch questionnaire): By placing a check mark in one 
box in each group below, please indicate which statement 
best describes your own state of health. The cognition bolt-
on item was worded as follows: cognition (such as memory, 
concentration). The answer options were: I have no problems 
with my cognitive functioning; I have some problems with 
my cognitive functioning; I have severe problems with my 
cognitive functioning.
Data analysis
The data analyses were performed with SPSS version 24. 
The responses of the patients to the question on the high-
est level of education were categorized in a variable with 
the values low, medium, and high education level. Comor-
bidity status was determined per patient as the number of 
pre-existing conditions. Respondents were included in the 
analyses if all questions of the EQ-5D including the cogni-
tion dimension and the EQ-VAS score were answered. The 
frequencies of the socio-demographics were determined 
with frequency analyses in SPSS. Furthermore, independ-
ent sample t tests were performed on the frequencies of the 
socio-demographics, comparing the group of TBI patients 
with the group of non-TBI patients. To determine whether 
there was a distributional effect in terms of ceiling effect, 
the proportion of perfect health profiles (11111 for EQ-5D 
and 111111 for EQ-5D + C) among all observed profiles was 
determined (the higher the share, the more ceiling).
The convergent validity of the EQ-5D and the EQ-5D + C 
was measured by determining the association between the 
EQ-VAS, the EQ-5D, and the EQ-5D + C, respectively. We 
first calculated the misery index for both the EQ-5D and the 
EQ-5D + C, consisting of the sum of the levels of the five 
dimensions (e.g., health profile 11111 had a misery index of 
5), where the highest score 15 represents the poorest health. 
Next, Spearman’s rank correlation coefficients between the 
EQ-5D and EQ-5D + C misery indices and EQ-VAS were 
determined for TBI and non-TBI patients, after it was con-
firmed that the assumptions of the Spearman’s rank correla-
tion were met [15].
In order to determine the explanatory power of EQ-5D 
and EQ-5D + C, we performed univariate and multivariable 
analyses using the EQ-VAS as dependent variable. With 
the univariate analyses we tested whether all dimensions 
of the EQ-5D(+ C) were related to the EQ-VAS. The levels 
‘some problems’ and ‘extreme problems’ of all dimensions, 
including the cognitive dimension, were used to predict the 
EQ-VAS. The two severity levels were recoded into dummy 
variables, with the ‘no problems’ level as the reference cat-
egory. With each of the dummy variables, the EQ-VAS score 
was then predicted. Thereafter, multivariable analyses were 
done, as the assumptions of the linear regression model were 
met, with different combinations of the dimensions of the 
EQ-5D and the cognitive dimension in the model. The com-
binations consisted of the original EQ-5D dimensions, the 
EQ-5D dimensions with the cognitive dimension, and all 
combinations of five out of the six dimensions. An addi-
tional model was tested for the EQ-5D and the EQ-5D + C 
for both groups with the backward deletion strategy.
To determine the classification efficiency of both the 
EQ-5D and the EQ-5D + C, the Shannon index (H’) and 
the Shannon Evenness index (J’) were determined [16]. 
These two indices provide information on the ability of the 
EQ-5D(+ C) to measure diversity in the population [17]. The 
Shannon index was calculated with the following formula: 
H′ = − ∑ci=1 pi 2log pi, where  pi is the proportion of people 
with a certain health profile, and C is the total number of 
possible health profiles. The higher the value of H′, the more 
information is captured by the EQ-5D or EQ-5D + C. The 
total number of possible health profiles is 3*3*3*3*3 = 243 
for the EQ-5D, and 729 for the EQ-5D + C. The Shan-
non Evenness index was calculated with the formula: J′ = 
H′/H′max, where H′max is 2logC and indicates the total num-
ber of possible health profiles. The Shannon Evenness index 
increases if the extra dimension is used to make more dis-
tinction between patients and flattens the distribution into 
more different health profiles [18]. According to Pielou 
[19], any assessment of H′ using a sample of the total ‘true’ 
population will lead to an underestimation of information 
captured, with a magnitude of (C − 1)/2N. This underesti-
mation may be considerable when C is large such as in the 
EQ-5D, but especially EQ-5D + C. Therefore, we also cal-
culated adjusted values of H′ and J′, taking this underestima-
tion bias into account.
Hypotheses
The following five hypotheses were formulated:
– The ceiling with the EQ-5D + C is less than with the 
EQ-5D;
– The convergent validity of the EQ-5D + C with the EQ-
VAS is higher than the convergent validity of the EQ-5D 
with the EQ-VAS in the group of TBI patients;
– The explanatory power of the EQ-5D + C is higher com-
pared to the EQ-5D in TBI patients due to specific cogni-
tive symptoms after TBI;
– The explanatory power of the EQ-5D is higher in non-
TBI patients than in TBI patients due to more heteroge-
neity in type and nature of injury;
– Absolute classification efficiency of the EQ-5D + C 
is higher compared to the EQ-5D in the group of TBI 
patients, while relative classification efficiency is similar.




The flow chart of the selection of the study population can 
be found in Fig. 1. In total, 9774 people received a ques-
tionnaire 1 month after injury. Out of these 9774 people, 
2693 (27.6%) filled out each item of the EQ-5D + C and 
EQ-VAS. Approximately, one in four was diagnosed with 
TBI (n = 715; 26.6%), where the majority of the TBI patients 
suffered from mild TBI (n = 550; 76.9%). The socio-demo-
graphics of the respondents are summarized in Table 1. The 
proportion of males was significantly higher for the group 
of TBI respondents (57.3%) than for the group of non-
TBI respondents (48.4%) (p < 0.05). TBI patients reported 
problems most frequently on the pain dimension (70.1%), 
whereas the non-TBI patients reported problems most fre-
quently on the usual activities dimension (87.3%). The aver-
age ISS score was significantly higher for the group of non-
TBI respondents than for the group of TBI respondents (6.83 
vs. 6.05, p < 0.05).
Frequency of unique health states and ceiling 
effects
Of the 2693 respondents, 214 people (7.9%) reported a 
perfect health state on the EQ-5D, and 197 (7.3%) on the 
EQ-5D + C. In the group of TBI patients, there were 129 
(18.0%) with perfect health on the EQ-5D, and 117 (16.4%) 
with perfect health on the EQ-5D + C. In the non-TBI group, 
the numbers were 85 (4.3%) for the EQ-5D, and 80 (4.0%) 
for the EQ-5D + C.
Convergent validity
Table 2 shows that convergent validity was highest for TBI 
group (EQ-5D + C: Spearman’s rank correlation coefficient 
= − 0.736; EQ-5D: Spearman’s rank correlation coefficient 
= − 0.719) and lowest in the non-TBI group (EQ-5D + C: 
Spearman’s rank correlation coefficient = − 0.665; EQ-5D: 
Spearman’s rank correlation coefficient = − 0.652). Note 
that health increases with a lower score in EQ-5D misery 
index and a higher score in EQ-VAS.
Explanatory power
The univariate regression analyses of the EQ-5D + C 
dimensions showed that all dimensions were significantly 
associated with the EQ-VAS score in both the group of 
TBI patients and the group of non-TBI patients (Appendix 
Table 5). The observed directions of the dimension effects 
were in all cases as expected (more problems, negative coef-
ficient), except for the level 2 effect of usual activities in the 
non-TBI group. Also, the magnitude of the effects (level 
3 larger than level 2) generally conformed to the expecta-
tions. The explained variance of the EQ-VAS was in the 
TBI group highest for usual activity level 3 (24.3%). In the 
non-TBI group, the explained variance of the EQ-VAS was 
highest for self-care level 3 and usual activities level 3 (both 
Fig. 1  Patient flow chart
Research populaon n=9774
Filled out EQ-5D+C quesonnaire aer 
1 month n = 2693











Number of paents with no TBI
n = 1978
1935Quality of Life Research (2019) 28:1931–1939 
1 3
20.4%). The explained variance of the EQ-VAS by the cog-
nition dimension was higher in the TBI group than in the 
non-TBI group for level 2, as expected, but lower for level 
3, which was unexpected (8.0% for level 2 and 9.9% for level 
3 vs. 4.5% for level 2 and 12.0% for level 3).
The results of the multivariable regression analyses of 
the group of TBI patients and non-TBI patients are dis-
played in Table 3. Generally, 55% of the variance of the 
EQ-VAS could be explained in TBI patients, and 45% 
in non-TBI patients. Adding the cognition dimension to 
the EQ-5D model resulted in an increase in explanatory 
power from 52.8 to 56.0% for the TBI group, and from 
45.1 to 46.6% for the non-TBI group. A mutual compari-
son of explanatory power of all five different selections of 
five dimensions from six dimensions resulted in similar 
explained variances, ranging from 52.8 to 54.6% in TBI 
patients and 43.3 to 45.4% in non-TBI patients (see also 
Fig. 2). The models with additional explanatory variables, 
resulting from the backward deletion strategy, did provide 
little additional explanatory power in all cases, except for 
the EQ-5D + C for TBI patients, where it provided no extra 
power. The model for the EQ-5D for TBI patients provided 
an additional explanatory power of 0.9% when the vari-
able ‘Number of TBIs’ was added. For the group of non-
TBI patients, an additional explanatory power of 1.1% was 
found for the EQ-5D + C when the ISS and the number of 
comorbidities were added, and an additional explanatory 
power of 1.5% in the EQ-5D when the same two variables 
were added.
Table 1  Characteristics of 
research population
SD standard deviation
*Significant at 5% level
a 80 missing values
b 26 missing values
c 54 missing values
d 17 missing values
Demographics of research population Research population TBI Non-TBI p value
n 2693 715 1978
Mean age (SD) 64.0 (18.3) 61.4 (18.6) 65.0 (18.1) < 0.001*
Females 1326 (49.2%) 305 (42.7%) 1021 (51.6%) < 0.001*
Education level
 Low 898 (33.3%)a 233 (32.6%)b 665 (33.6%)c 0.616
 Medium 963 (35.8%)a 258 (36.1%)b 705 (35.6%)c 0.833
 High 752 (27.9%)a 198 (27.7%)b 554 (28.0%)c 0.872
ISS scores
 1–3 609 (22.6%)d 358 (50.1%) 251 (12.7%)d < 0.001*
 4–8 921 (34.2%)d 169 (23.6%) 752 (38.0%)d < 0.001*
 9–15 1005 (37.3%)d 125 (17.5%) 880 (44.5%)d < 0.001*
 16+ 141 (5.2%)d 63 (8.8%) 78 (3.9%)d < 0.001*
Severity of TBI
 Mild – 550 (76.9%) – –
 Moderate – 65 (9.1%) – –
 Severe – 100 (14.0%) – –
Comorbidity
 n pre-existing conditions
  0 1061 (39.4%) 306 (42.8%) 755 (38.2%) 0.032*
  1 724 (26.9%) 194 (27.1%) 530 (26.8%) 0.861
  2 441 (16.4%) 111 (15.5%) 330 (16.7%) 0.473
  3+ 467 (17.4%) 104 (14.5%) 363 (18.5%) 0.016*
Table 2  Spearman’s rank correlation sum score EQ-5D and EQ-VAS 




Research population EQ-5D – EQ-VAS − 0.673
EQ-5D + C – EQ-VAS − 0.690
TBI EQ-5D – EQ-VAS − 0.719
EQ-5D + C – EQ-VAS − 0.736
Non-TBI EQ-5D – EQ-VAS − 0.652
EQ-5D + C – EQ-VAS − 0.665
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Classification efficiency—Shannon’s indices
The number of different health profiles in the TBI group 
was considerably lower compared to the non-TBI group. 
In the group of TBI patients, 87 out of 243 (35.8%) pos-
sible EQ-5D profiles were used, and 153 out of 729 (21.0%) 
possible EQ-5D + C profiles were reported. In the group of 
non-TBI patients, 127 out of 243 (52.3%) possible EQ-5D 
profiles and 232 out of 729 (31.8%) possible EQ-5D + C 
profiles were reported. This was reflected in the Shannon 
index and the Shannon Evenness index, which were 5.08 
(Shannon index) and 0.64 (Shannon Evenness index) for 
the EQ-5D and 5.88 (Shannon index) and 0.62 (Shannon 
Evenness index) for the EQ-5D + C, respectively, for the 
TBI group, while for the non-TBI group the results were 
5.58 and 0.70 for the EQ-5D, and 6.38 and 0.67 for the 
EQ-5D + C (Table 4). Apart from the non-TBI group being 
more heterogeneous, this indicates that generally more 
information is captured by the EQ-5D + C compared to the 
EQ-5D. The Shannon Evenness index was higher for the 
EQ-5D than for the EQ-5D + C (J′ = 0.64 vs. J′ = 0.62 for 
TBI, and J′ = 0.70 vs. J′ = 0.67 for non-TBI), but were 
similar after adjusting for underestimation bias (J′adj = 0.66 
vs. J′adj = 0.67 for TBI, and J′adj = 0.71 vs. J′adj = 0.69 for 
non-TBI). Apparently, more information is captured but the 
observed gain in discrimination in both groups is relatively 
low in view of the increase of classification options (add-




This study addressed the potential gain of adding a cognitive 
dimension to the EQ-5D measure, in a large group of injury 
patients where this gain could be relevant in the subgroup of 
TBI patients. Genuinely it slightly improved ceiling effects 
and improved the ranking of patients if a self-rated VAS 
was used as reference. As expected, this effect was larger in 
TBI patients. However, the increase in explanatory power 
was rather small (3.2% if we focus on TBI). Furthermore, 
the added value in terms of explanatory power of the cogni-
tion dimension in the non-TBI population was close to zero, 
Table 3  Explanatory power of multivariable models for the EQ-VAS 
that include any combination of the EQ-5D and cognition dimensions 
for TBI and non-TBI patients
MO mobility, SC self-care, UA usual activities, PD pain/discomfort, 
AD anxiety/depression, CO cognition
*Significant at 5% level
Combination of EQ-5D + C 
dimensions
Adjusted R2 F value P value
Research population
 MO, SC, UA, PD, AD 0.480 249.1 < 0.001*
 MO, SC, UA, PD, AD, CO 0.499 224.5 < 0.001*
 MO, UA, PD, AD, CO 0.486 255.4 < 0.001*
 MO, SC, PD, AD, CO 0.477 246.8 < 0.001*
 MO, SC, UA, AD, CO 0.472 241.7 < 0.001*
 MO, SC, UA PD, CO 0.471 241.2 < 0.001*
 SC, UA, PD, AD, CO 0.487 256.4 < 0.001*
TBI patients
 MO, SC, UA, PD, AD 0.528 80.9 < 0.001*
 MO, SC, UA, PD, AD, CO 0.560 76.6 < 0.001*
 MO, UA, PD, AD, CO 0.546 86.7 < 0.001*
 MO, SC, PD, AD, CO 0.533 82.3 < 0.001*
 MO, SC, UA, AD, CO 0.530 81.5 < 0.001*
 MO, SC, UA PD, CO 0.546 86.8 < 0.001*
 SC, UA, PD, AD, CO 0.546 87.0 < 0.001*
Non-TBI patients
 MO, SC, UA, PD, AD 0.451 163.7 < 0.001*
 MO, SC, UA, PD, AD, CO 0.466 145.0 < 0.001*
 MO, UA, PD, AD, CO 0.452 164.3 < 0.001*
 MO, SC, PD, AD, CO 0.447 161.1 < 0.001*
 MO, SC, UA, AD, CO 0.441 157.2 < 0.001*
 MO, SC, UA PD, CO 0.433 151.9 < 0.001*


















EQ-5D+C dimensions in the model
TBI
non-TBI
Fig. 2  Adjusted R2 per EQ-5D dimensions included for TBI and non-
TBI patients for the EQ-VAS. M mobility, S self-care, U usual activi-
ties, P pain/discomfort, A anxiety/depression, C cognition
Table 4  Shannon index (H′) and Shannon Evenness index (J′) of 
EQ-5D and EQ-5D + C for TBI and non-TBI patients
Health profiles H′ Adjusted H′ J′ Adjusted J′
TBI
 EQ-5D 5.08 5.25 0.64 0.66
 EQ-5D + C 5.88 6.39 0.62 0.67
Non-TBI
 EQ-5D 5.58 5.64 0.70 0.71
 EQ-5D + C 6.38 6.56 0.67 0.69
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as expected. Discriminatory potential (informativity) was 
higher for the EQ-5D + C than for the EQ-5D in both groups, 
whereas relative informativity was similar.
Comparison to previous studies
The addition of a cognition dimension to the EQ-5D has 
been studied before, but not specifically in a population with 
TBI. Ophuis et al. (working paper) looked into the effect 
in a small group of TBI patients, but a clinical classifica-
tion of severity of the TBI was lacking. Moreover, in the 
study by Ophuis et al. (working paper) HRQoL was assessed 
2.5 months after ED treatment, whereas in this study the 
EQ-5D(+ C) was assessed 1 month after ED treatment, and 
as a result we expect that less patients fully recovered from 
their injuries. Despite these differences, the findings of the 
study by Ophuis et al. (working paper) were similar to our 
findings: compared to EQ-5D the increase in explanatory 
power of the EQ-5D + C is small (< 3%).
Findings of other studies on the cognition dimension are 
more difficult to compare. Krabbe et al. [10] looked into the 
effect of adding a cognition dimension to the EQ-5D; how-
ever, in this study the content validity was tested, as well as 
the impact on utilities. The study by Jelsma and Maart [7] 
looked into the effect of adding several dimensions, includ-
ing a concentration dimension, to the EQ-5D. Concentration 
is considered a part of the cognition dimension. The study 
by Jelsma and Maart [7] found that the addition of a con-
centration dimension increased the explanatory power of the 
model (52–55% when concentration, energy, body appear-
ance, sleep, and sexual activity were added). However, they 
did not report the increase in explanatory value for each 
extra dimension separately.
Convergent validity of the EQ-5D has been studied by 
Golicki et al. [20]. In this study, the convergent validity 
was determined for each dimension of the EQ-5D with the 
EQ-VAS, with the Spearman rank correlation coefficients 
ranging from − 0.43 for pain/discomfort to − 0.75 for usual 
activities [20]. These correlation coefficients are in the 
same order of magnitude compared to those we found for 
the EQ-5D and EQ-5D + C.
Previous studies on the classification efficiency of the 
EQ-5D found varying values for the Shannon index and the 
Shannon Evenness index of the EQ-5D. Janssen, Birnie, and 
Bonsel [21] found a Shannon index of 6.37 and a Shannon 
Evenness index of 0.80 in a general population sample from 
the US. Polinder et al. [22] reported a Shannon index for the 
EQ-5D of 2.71 and a Shannon Evenness index of 0.53 in an 
injury population. For skull and brain injury patients, this 
study reported a Shannon index of 2.55 for the EQ-5D and 
a Shannon Evenness index of 0.49 [22]. The Shannon index 
that was found in our injury population is higher (5.08 for TBI 
and 5.58 for non-TBI). This can be explained by the fact that 
the measurement of HRQoL in our study was conducted 1 
month after presentation at the ED, versus 2 years after injury. 
Therefore, it is likely that there was a larger variation of health 
profiles in our study than in the study by Polinder et al. [22], 
resulting in a higher Shannon index and Shannon Evenness 
index. It should be taken into account that the ceiling effect 
is also part of the formula to determine the classification effi-
ciency. However, in calculating the classification efficiency it 
is not relevant whether a high frequency of one health profile 
is in the perfect health profile (11111) or in another health 
profile. Therefore, if a health profile is overrepresented, this 
will result in a smaller classification efficiency.
Strengths and limitations
This study had several strengths and limitations. One of 
the strengths was that diagnosis and severity of TBI was 
registered. A limitation of this study was the timing of the 
HRQoL assessment. A study by Schretlen and Shapiro [23] 
found that cognitive functioning after mild TBI restores 
within 1–3 months. Since the majority of patients in the TBI 
group had mild TBI, patients may have already recovered 
1 month after presentation at the ED. The BIOS study also 
contains data on a 1-week measurement; however, the num-
ber of respondents at this point is rather small. Secondly, 
the group of non-TBI patients had on average a significantly 
higher ISS score, indicating that this group of patients sus-
tained more severe injuries compared to the group of TBI 
patients. This is reflected by the much higher proportion of 
patients in the TBI group who reported perfect health. The 
EQ-5D was found to suffer from ceiling effect, meaning that 
health states close to good health cannot be distinguished 
well [18, 24]. Therefore, the ceiling effect was larger in the 
TBI group than in the non-TBI group. A question that arises 
is whether the ceiling effect in the TBI group (18.0% for 
EQ-5D and 16.4% for EQ-5D + C) would have been reduced 
when the EQ-5D-5L or EQ-5D-5L + C was used, as is sug-
gested by Janssen et al. [18]. Respondents with minor com-
plaints on one of the dimensions will choose ‘no problems’ 
in the EQ-5D-3L, but are likely to choose ‘slight problems’ 
in the EQ-5D-5L.
For future research, we recommend to assess the added 
value of the cognitive bolt-on for the EQ-5D-5L and to 
include more patients with moderate or severe TBI to enable 
a comparison between the severity levels of TBI. Further-
more, we recommend to develop guidelines to determine 
what a meaningful difference, in a statistical sense, of a bolt-
on is.
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Conclusion
In conclusion, the addition of a cognition dimension to 
the EQ-5D improves the convergent validity, explana-
tory power, and classification efficiency of the EQ-5D. 
However, improvements are rather small. The effect on 
the convergent validity and the explanatory power of the 
EQ-5D is larger in the group of TBI patients than in the 
group of non-TBI patients, suggesting that the additional 
value of a cognition dimension in the EQ-5D is especially 
relevant in a patient group with (expected) problems with 
cognition.
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Appendix
Table 5  Univariate analyses 
of EQ-VAS explained by 
the EQ-5D and cognition 
dimensions for TBI and non-
TBI patients
95% CI = 95% confidence interval
*Significant at 5% level
EQ-5D dimension R2 Unstandardized B (95% CI) p value
TBI patients
 Mobility level 2 0.116 − 13.4 (− 16.1 to − 10.7) < 0.001*
 Mobility level 3 0.109 − 33.3 (− 40.3 to − 26.3) < 0.001*
 Self-care level 2 0.076 − 12.1 (− 15.3 to − 9.0) < 0.001*
 Self-care level 3 0.156 − 28.3 (− 33.2 to − 23.5) < 0.001*
 Usual activities level 2 0.009 − 3.7 (− 6.6 to − 0.9) 0.005*
 Usual activities level 3 0.243 − 24.2 (− 27.3 to − 21.0) < 0.001*
 Pain/discomfort level 2 0.038 − 7.8 (− 10.8 to − 4.9) < 0.001*
 Pain/discomfort level 3 0.131 − 26.3 (− 31.3 to 21.3) < 0.001*
 Anxiety/depression level 2 0.123 − 15.4 (− 18.4 to − 12.4) < 0.001*
 Anxiety/depression level 3 0.062 − 25.5 (− 32.8 to − 18.2) < 0.001*
 Cognition level 2 0.080 − 11.7 (− 14.5 to − 8.8) < 0.001*
 Cognition level 3 0.099 − 29.7 (− 36.3 to − 23.1) < 0.001*
Non-TBI patients
 Mobility level 2 0.005 − 2.8 (− 4.6 to − 1.1) 0.002*
 Mobility level 3 0.114 − 20.1 (− 22.6 to − 17.7) < 0.001*
 Self-care level 2 0.002 − 1.8 (− 3.5 to − 0.1) 0.043*
 Self-care level 3 0.204 − 23.6 (− 25.6 to − 21.5) < 0.001*
 Usual activities level 2 0.050 8.8 (7.1 to 10.5) < 0.001*
 Usual activities level 3 0.204 − 18.0 (− 19.6 to − 16.5) < 0.001*
 Pain/discomfort level 2 0.003 − 2.4 (− 4.3 to − 0.5) 0.014*
 Pain/discomfort level 3 0.088 − 19.8 (− 22.6 to − 17.0) < 0.001*
 Anxiety/depression level 2 0.095 − 13.3 (− 15.1 to − 11.5) < 0.001*
 Anxiety/depression level 3 0.102 − 28.4 (− 32.1 to − 24.7) < 0.001*
 Cognition level 2 0.045 − 9.9 (− 11.9 to − 7.9) < 0.001*
 Cognition level 3 0.120 − 26.5 (− 29.7 to − 23.4) < 0.001*
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